Literature DB >> 27900044

Plumbagin inhibits cell proliferation and promotes apoptosis in multiple myeloma cells through inhibition of the PI3K/Akt-mTOR pathway.

Hongwei Wu1, Xiaozhen Dai2, Enren Wang3.   

Abstract

Plumbagin is the primary component of the traditional Chinese medicine Baihua Dan, and possesses anti-infection and anticancer effects with the ability to enhance the sensitivity of tumor cells to radiation therapy. The present study aimed to investigate the potential anticancer effect and mechanism of plumbagin on multiple myeloma (MM) cells. Human MM OPM1 cells were treated with plumbagin, and its impact on cell viability, cytotoxicity, apoptosis and caspase-3 activity was examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, lactate dehydrogenase leakage, flow cytometry and colorimetric assays. In addition, the protein expression levels of phosphoinositide 3-kinase, phosphorylated (p)-Akt and p-mammalian target of rapamycin (mTOR) in OPM1 cells were analyzed by western blotting. The results demonstrated that plumbagin treatment inhibited cell viability, increased cell cytotoxicity, activated cell apoptosis and promoted caspase-3 activity in the OPM1 cells. Furthermore, pretreatment of plumbagin significantly suppressed PI3K, p-Akt and p-mTOR protein expression levels in the OPM1 cells. In conclusion, the present study indicates that plumbagin inhibits cell proliferation and promotes apoptosis in MM cells through inhibition of PI3K/Akt-mTOR expression.

Entities:  

Keywords:  PI3K/Akt-mTOR; multiple myeloma; plumbagin

Year:  2016        PMID: 27900044      PMCID: PMC5104058          DOI: 10.3892/ol.2016.5048

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro.

Authors:  Yang Yang; Xiaoxi Zhou; Min Xiao; Zhenya Hong; Quan Gong; Lijun Jiang; Jianfeng Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

2.  Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.

Authors:  Yan-Cong Li; Shu-Ming He; Zhi-Xu He; Minghua Li; Yinxue Yang; Jian-Xin Pang; Xueji Zhang; Kevin Chow; Qingyu Zhou; Wei Duan; Zhi-Wei Zhou; Tianxin Yang; Gui-Hua Huang; Aibing Liu; Jia-Xuan Qiu; Jun-Ping Liu; Shu-Feng Zhou
Journal:  Cancer Lett       Date:  2013-11-23       Impact factor: 8.679

3.  Plumbagin inhibits LPS-induced inflammation through the inactivation of the nuclear factor-kappa B and mitogen activated protein kinase signaling pathways in RAW 264.7 cells.

Authors:  Tingyu Wang; Feihua Wu; Zhigui Jin; Zanjing Zhai; Yugang Wang; Bing Tu; Wei Yan; Tingting Tang
Journal:  Food Chem Toxicol       Date:  2013-12-01       Impact factor: 6.023

Review 4.  Perspectives on medicinal properties of plumbagin and its analogs.

Authors:  Subhash Padhye; Prasad Dandawate; Mujahid Yusufi; Aamir Ahmad; Fazlul H Sarkar
Journal:  Med Res Rev       Date:  2010-11-09       Impact factor: 12.944

Review 5.  Current and future imaging modalities for multiple myeloma and its precursor states.

Authors:  Esther Tan; Brendan M Weiss; Esther Mena; Neha Korde; Peter L Choyke; Ola Landgren
Journal:  Leuk Lymphoma       Date:  2011-06-08

6.  Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.

Authors:  M Koldehoff; D W Beelen; A H Elmaagacli
Journal:  Cancer Gene Ther       Date:  2014-06-06       Impact factor: 5.987

7.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Authors:  Hongbing Zhang; Natalia Bajraszewski; Erxi Wu; Hongwei Wang; Annie P Moseman; Sandra L Dabora; James D Griffin; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2007-02-08       Impact factor: 14.808

Review 8.  Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.

Authors:  Ota Fuchs
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2013-03-01

9.  Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells.

Authors:  Feng Wang; Qi Wang; Zhi-Wei Zhou; Song-Ning Yu; Shu-Ting Pan; Zhi-Xu He; Xueji Zhang; Dong Wang; Yin-Xue Yang; Tianxing Yang; Tao Sun; Min Li; Jia-Xuan Qiu; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-01-17       Impact factor: 4.162

10.  Plumbagin reduces human colon cancer cell survival by inducing cell cycle arrest and mitochondria-mediated apoptosis.

Authors:  Binil Eldhose; Mia Gunawan; Mahbubur Rahman; Mukalel S Latha; Vicente Notario
Journal:  Int J Oncol       Date:  2014-08-08       Impact factor: 5.650

View more
  9 in total

1.  Plumbagin induces ROS-mediated apoptosis and cell cycle arrest and inhibits EMT in human cervical carcinoma cells.

Authors:  Ankita Jaiswal; Akash Sabarwal; Jai Prakash Narayan Mishra; Rana P Singh
Journal:  RSC Adv       Date:  2018-09-17       Impact factor: 4.036

2.  Resibufogenin inhibits the malignant characteristics of multiple myeloma cells by blocking the PI3K/Akt signaling pathway.

Authors:  Yan Zhou; Zirui Hong; Keting Jin; Chenjun Lin; Jingjing Xiang; Hangping Ge; Zhiyin Zheng; Jianping Shen; Shu Deng
Journal:  Exp Ther Med       Date:  2022-05-13       Impact factor: 2.751

Review 3.  Phytochemicals and PI3K Inhibitors in Cancer-An Insight.

Authors:  Vasanti Suvarna; Manikanta Murahari; Tabassum Khan; Pramila Chaubey; Preeti Sangave
Journal:  Front Pharmacol       Date:  2017-12-14       Impact factor: 5.810

4.  Discovery and cellular stress pathway analysis of 1,4-naphthoquinone derivatives with novel, highly potent broad-spectrum anticancer activity.

Authors:  Sajal K Ghosh; Abhishek Ganta; Remco A Spanjaard
Journal:  J Biomed Sci       Date:  2018-02-08       Impact factor: 8.410

5.  Plumbagin Prevents Secretory Diarrhea by Inhibiting CaCC and CFTR Channel Activities.

Authors:  Bo Yu; Xiaojuan Zhu; Xinyu Yang; Lingling Jin; Jia Xu; Tonghui Ma; Hong Yang
Journal:  Front Pharmacol       Date:  2019-10-09       Impact factor: 5.810

6.  Plumbagin Suppresses Breast Cancer Progression by Downregulating HIF-1α Expression via a PI3K/Akt/mTOR Independent Pathway under Hypoxic Condition.

Authors:  Supawan Jampasri; Somrudee Reabroi; Duangjai Tungmunnithum; Warisara Parichatikanond; Darawan Pinthong
Journal:  Molecules       Date:  2022-09-05       Impact factor: 4.927

7.  Plumbagin inhibits proliferation and promotes apoptosis of ovarian granulosa cells in polycystic ovary syndrome by inactivating PI3K/Akt/mTOR pathway.

Authors:  Zhaowei Cai; Shaojuan He; Tao Li; Li Zhao; Kerong Zhang
Journal:  Anim Cells Syst (Seoul)       Date:  2020-07-17       Impact factor: 1.815

Review 8.  Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

Authors:  Sabah Akhtar; Tayyiba A Ali; Ammara Faiyaz; Omar S Khan; Syed Shadab Raza; Michal Kulinski; Halima El Omri; Ajaz A Bhat; Shahab Uddin
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

9.  Plumbagin attenuates traumatic tracheal stenosis in rats and inhibits lung fibroblast proliferation and differentiation via TGF-β1/Smad and Akt/mTOR pathways.

Authors:  Wei Shi; Yuanyuan Fang; Yueming Jiang; Siyang Jiang; Yu Li; Wentao Li; Mingpeng Xu; Michael Aschner; Guangnan Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.